Bath & Body Works, Inc. (NYSE:BBWI - Get Free Report) shares rose 4% during mid-day trading on Monday . The company traded as high as $31.04 and last traded at $30.75. Approximately 1,289,280 shares traded hands during trading, a decline of 75% from the average daily volume of 5,155,768 shares. The stock had previously closed at $29.58.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on BBWI. Piper Sandler upgraded shares of Bath & Body Works from a "neutral" rating to an "overweight" rating and lowered their price target for the stock from $38.00 to $35.00 in a report on Wednesday, April 9th. Citigroup decreased their target price on Bath & Body Works from $48.00 to $36.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Wells Fargo & Company dropped their price target on Bath & Body Works from $48.00 to $40.00 and set an "overweight" rating on the stock in a research note on Wednesday. Cowen reaffirmed a "buy" rating on shares of Bath & Body Works in a research report on Thursday, February 27th. Finally, Robert W. Baird boosted their target price on shares of Bath & Body Works from $45.00 to $47.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $42.19.
Read Our Latest Stock Report on BBWI
Bath & Body Works Stock Performance
The company's 50 day moving average price is $30.42 and its 200-day moving average price is $33.82. The stock has a market cap of $6.64 billion, a P/E ratio of 7.60, a price-to-earnings-growth ratio of 0.92 and a beta of 1.69.
Bath & Body Works (NYSE:BBWI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $2.09 EPS for the quarter, beating the consensus estimate of $2.04 by $0.05. Bath & Body Works had a net margin of 12.43% and a negative return on equity of 44.03%. The firm had revenue of $2.79 billion during the quarter, compared to analyst estimates of $2.78 billion. On average, analysts forecast that Bath & Body Works, Inc. will post 3.3 earnings per share for the current fiscal year.
Bath & Body Works Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Shareholders of record on Friday, February 21st were given a $0.20 dividend. The ex-dividend date was Friday, February 21st. This represents a $0.80 annualized dividend and a yield of 2.57%. Bath & Body Works's dividend payout ratio is currently 21.98%.
Bath & Body Works announced that its board has approved a share buyback program on Thursday, February 27th that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board of directors believes its stock is undervalued.
Hedge Funds Weigh In On Bath & Body Works
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Bath & Body Works by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 28,199,787 shares of the company's stock valued at $1,093,306,000 after acquiring an additional 208,036 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Bath & Body Works by 4.3% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,235,086 shares of the company's stock valued at $396,815,000 after purchasing an additional 422,973 shares during the period. Price T Rowe Associates Inc. MD increased its position in Bath & Body Works by 5.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,494,089 shares of the company's stock worth $329,317,000 after buying an additional 445,887 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Bath & Body Works by 14,732.0% in the first quarter. Victory Capital Management Inc. now owns 6,798,108 shares of the company's stock valued at $206,119,000 after buying an additional 6,752,274 shares during the period. Finally, Alliancebernstein L.P. lifted its position in shares of Bath & Body Works by 35.6% during the 4th quarter. Alliancebernstein L.P. now owns 5,178,447 shares of the company's stock valued at $200,768,000 after buying an additional 1,360,264 shares during the last quarter. 95.14% of the stock is owned by hedge funds and other institutional investors.
Bath & Body Works Company Profile
(
Get Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
Read More
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.